Vaxcyte Reports Second Quarter 2023 Financial Results and :

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...

Related Keywords

Jennifer Zibuda , Janet Graesser , Michaele Kamarck , Advisory Committee On Immunization Practices , University Of Maryland , Sutro Biopharma Inc , Research Development Rd Expenses , Exchange Commission , Vaxcyte Inc , Company Phase , National Institutes Of Health , Groupa Strep , Drug Administration , Adult Program , Nasdaq , Corporate Communications , Second Stage , Dosing First New Participants , Topline Data , Primary Immunization Series Expected , Invasive Pneumococcal Disease , Topline Phase , Investigational New Drug , Application Clearance Expected , Fourth Quarter , Cash Equivalents , Including Net Proceeds , April Public , Advisory Committee , Immunization Practices , Grant Pickering , Chief Executive Officer , Second Quarter , Recent Highlights , Positive Data , Full Six Month Safety Data , Adult Phase , Final Stage , Dosed First New Participants , Data Safety Monitoring Board , Follow On Financing , Novel Shigellao Polysaccharide , Confers Protection , Multiple Shigella Serotypes , National Institutes , Biologics License Application , Breakthrough Therapy , Sutro Biopharma , Private Securities Litigation Reform Act , Quarterly Report , Vice President , Investor Relations , Senior Director , Months Ended June , Nasdaq Pcvx , Maxcyte , Nc , Biotech , Vaccines , Healthcare ,